{
  "docId": "019de517-1302-72c9-b1b1-402f68725e8a",
  "docSlug": "8240d0b9060d59c07a4e5f5063c97322",
  "documentTitle": "Adagio Therapeutics | Results Presentation Deck | 11 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 11,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "propose_solution",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/9",
  "deckHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a",
  "deckJsonHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json",
  "deckAnchorHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.11,
        "w": 0.86,
        "x": 0.07,
        "y": 0.79
      },
      "kind": "image",
      "text": "COMIRNATY (COVID-19 Vaccine, mRNA)\nTivicay (dolutegravir) tablets 10 mg | 25 mg | 50 mg\nTriumeq dolutegravir/abacavir/lamivudine\nFetroja (cefiderocol) for injection\nMENVEO Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CR M197 Conjugate Vaccine\nOnce-A-Day CUBICIN (daptomycin for injection",
      "attrs": {},
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5092d056-5eb2-48bd-bf47-a1716524128d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.309,
        "w": 0.869,
        "x": 0.055,
        "y": 0.254
      },
      "kind": "list",
      "text": "Go-to-market planning (e.g., market research, market sizing/segmentation, brand strategy, field force sizing)\nMarket access activities (e.g., payer/pricing research, distribution channels)\nManufacturing initial commercial inventory\nEstablishing necessary internal systems and technology to support the transition to commercial stage",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20416dd3-fb1e-4b15-a079-a4d14d317728",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.783,
        "x": 0.107,
        "y": 0.673
      },
      "kind": "paragraph",
      "text": "Commercial preparations are being led by a seasoned team with extensive experience successfully commercializing products within the infectious disease space, such as:",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31379fc1-114b-4120-8019-0c76db8144fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.07,
        "x": 0.85,
        "y": 0.954
      },
      "kind": "source-note",
      "text": "INVIVYD",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67db183f-99f6-4649-94b2-933c9eef374c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.889,
        "x": 0.045,
        "y": 0.063
      },
      "kind": "title",
      "text": "COMMERCIALIZATION PREPARATIONS ARE UNDERWAY FOR POTENTIAL VYD222 LAUNCH IN THE U.S., IF AUTHORIZED",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd2b95fc-2d8d-4967-a6c9-1737fa316956",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 9,
      "beatId": "feb56317-a2e6-4f8a-8b39-db8ce0bbaf5d",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The commercialization preparations and financial overview outline the next steps",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d0bf14cf-88e0-4c86-bb16-82a24eeb0889",
      "evidence": "The presentation highlights the urgent need for protection and the potential consequences of inaction",
      "position": 0,
      "objective": "What is the cost of not protecting immunocompromised individuals from COVID-19?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}